<DOC>
	<DOCNO>NCT01099774</DOCNO>
	<brief_summary>This study evaluate safety efficacy bimatoprost 0.03 % formulation B ophthalmic solution LUMIGANÂ® ( bimatoprost ophthalmic solution 0.03 % ) daily 12 week patient glaucoma ocular hypertension</brief_summary>
	<brief_title>Safety Efficacy Different Formulations Bimatoprost Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient ocular hypertension glaucoma eye Requires IOPlowering therapy eye Active recurrent eye disease would interfere interpretation study data either eye History eye surgery laser either eye within 6 month Required chronic use eye medication study Anticipated wear contact lens study . Intermittent use oral , intramuscular , intravenous corticosteroid within 21 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>